Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

被引:5
|
作者
Holzhauer, Bjorn [1 ]
机构
[1] Novartis Pharma AG, Biostat Sci & Pharmacometr, Basel, Switzerland
来源
关键词
Bayesian model averaging; Rare events; Robust meta-analytic predictive prior; Safety meta-analysis; Shrinkage priors; ANALYTIC-PREDICTIVE PRIORS; INFORMATION;
D O I
10.1080/19466315.2019.1610043
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article deals with comparing a test with a control therapy using meta-analyses of data from randomized controlled trials with a time-to-event endpoint. Such analyses can often benefit from prior information about the distribution of control group outcomes. One possible source of this information is the published aggregate data about control groups of historical trials from the medical literature. We review methods for making posterior inference about exponentially distributed event times more robust to prior-data conflicts by discounting the prior information based on the extent of observed prior-data conflict. We use simulations to compare analyses without prior information with the meta-analytic combined, meta-analytic predictive and robust meta-analytic predictive approaches, as well as Bayesian model averaging using shrinkage priors. Bayesian model averaging via shrinkage priors with well-chosen hyperpriors performed best in terms of credible interval coverage and mean-squared error across scenarios. For the robust meta-analytic predictive approach, there was little benefit in increasing the weight of the informative mixture components beyond 0.2-0.5. This was the case even when little prior-data conflict was expected, except with very sparse data or substantial between-trial heterogeneity in control group hazard rates. for this article are available online.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 50 条
  • [41] Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials
    Fiteni, Frederic
    Paillard, Marie-Justine
    Westeel, Virginie
    Bonnetain, Franck
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 167 - 173
  • [42] Predicting events in clinical trials using two time-to-event outcomes
    Mu, Rongji
    Xu, Jin
    BIOMETRICAL JOURNAL, 2018, 60 (04) : 815 - 826
  • [43] Low-event-rate meta-analyses of clinical trials: implementing good practices
    Shuster, Jonathan J.
    Walker, Michael A.
    STATISTICS IN MEDICINE, 2016, 35 (14) : 2467 - 2478
  • [44] Case weighted power priors for hybrid control analyses with time-to-event data
    Kwiatkowski, Evan
    Zhu, Jiawen
    Li, Xiao
    Pang, Herbert
    Lieberman, Grazyna
    Psioda, Matthew A.
    BIOMETRICS, 2024, 80 (02)
  • [45] An evaluation of computational methods for aggregate data meta-analyses of diagnostic test accuracy studies
    Zhao, Yixin
    Khan, Bilal
    Negeri, Zelalem F.
    BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [46] Practical methods for incorporating summary time-to-event data into meta-analysis
    Jayne F Tierney
    Lesley A Stewart
    Davina Ghersi
    Sarah Burdett
    Matthew R Sydes
    Trials, 8
  • [47] How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials
    Sofeu, Casimir Ledoux
    Rondeau, Virginie
    PLOS ONE, 2020, 15 (01):
  • [48] Practical methods for incorporating summary time-to-event data into meta-analysis
    Tierney, Jayne F.
    Stewart, Lesley A.
    Ghersi, Davina
    Burdett, Sarah
    Sydes, Matthew R.
    TRIALS, 2007, 8 (1)
  • [49] A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses
    Rotolo, Federico
    Paoletti, Xavier
    Burzykowski, Tomasz
    Buyse, Marc
    Michiels, Stefan
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2019, 28 (01) : 170 - 183
  • [50] Bayesian Design of Clinical Trials Using Joint Cure Rate Models for Longitudinal and Time-to-Event Data
    Jiawei Xu
    Matthew A. Psioda
    Joseph G. Ibrahim
    Lifetime Data Analysis, 2023, 29 : 213 - 233